NextGenerationEU

Home Tag

Sin título (1300 x 600 px) (1)

First MYC inhibitor to demonstrate safety and anti-tumor activity in a phase I first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…

Banner web VHIO (1300 × 600 px) (36)

The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first MYC oncogene inhibitor

The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…